Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Shelley Wood

February 28, 2017

News Daily News

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

Michael O'Riordan

February 14, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

Advertisement

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Statins and Diabetes: Causal Link Reinforced in New Analysis

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content